Qube Research & Technologies (QRT)
RLAY icon

Qube Research & Technologies (QRT)’s Relay Therapeutics RLAY Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-619,652
Closed -$6.17M – 3972
2026
Q1 		$6.17M Buy
+619,652
New +$5.54M 0.01% 1553
2025
Q1 		– Sell
-87,863
Closed -$362K – 3814
2024
Q4 		$362K Buy
+87,863
New +$478K ﹤0.01% 2631
2024
Q3 		– Sell
-156,254
Closed -$1.02M – 3975
2024
Q2 		$1.02M Buy
156,254
+18,820
+14% +$129K ﹤0.01% 1883
2024
Q1 		$1.14M Buy
137,434
+102,472
+293% +$1,000K ﹤0.01% 2066
2023
Q4 		$385K Buy
+34,962
New +$295K ﹤0.01% 2443
2023
Q3 		– Sell
-16,777
Closed -$211K – 4290
2023
Q2 		$211K Sell
16,777
-23,302
-58% -$290K ﹤0.01% 1764
2023
Q1 		$660K Sell
40,079
-2,523
-6% -$45.2K ﹤0.01% 1457
2022
Q4 		$636K Buy
+42,602
New +$815K ﹤0.01% 1387
2022
Q3 		– Sell
-59,484
Closed -$996K – 2937
2022
Q2 		$996K Buy
+59,484
New +$1.27M 0.01% 1105

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RLAY Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 619,652 shares — an estimated $6.17M sold.

Qube Research & Technologies (QRT) first reported a position in RLAY in Q2 2022 and held it in 9 quarters. The position peaked at $6.17M in Q1 2026. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 619,652 Relay Therapeutics shares in Q2 2026, an estimated $6.17M.
  • Qube Research & Technologies (QRT) first reported a position in Relay Therapeutics in Q2 2022 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Relay Therapeutics position peaked at $6.17M in Q1 2026.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.